369 related articles for article (PubMed ID: 25336456)
21. Prevalence, Transmission and Genetic Diversity of Pyrazinamide Resistance Among Multidrug-Resistant
Liu B; Su P; Hu P; Yan M; Li W; Yi S; Chen Z; Zhang X; Guo J; Wan X; Wang J; Gong D; Bai H; Wan K; Liu H; Li G; Tan Y
Infect Drug Resist; 2024; 17():403-416. PubMed ID: 38328339
[TBL] [Abstract][Full Text] [Related]
22. Exploring of pyrazinamidase recombinant activity from PZA-sensitive and resistant Mycobacterium tuberculosis expressed in Escherichia coli BL21 (DE3).
Purkan P; Hadi S; Retnowati W; Sumarsih S; Wahyuni DK; Piluharto B; Panjaitan TM; Ifada C; Nadila A; Nabilah BA
Braz J Biol; 2024; 84():e278911. PubMed ID: 38422295
[TBL] [Abstract][Full Text] [Related]
23. Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients.
Li R; Li Y; Chen X; Jia L; Yu H; Huang Y; Wu Q; Xiao M; Ge S; Zhang Y; Feng Z; Li Q; Xu Y; Shi W; Sun F; Zhang W
Microbiol Spectr; 2023 Jun; 11(3):e0483622. PubMed ID: 37162355
[TBL] [Abstract][Full Text] [Related]
24. Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.
Hegde PV; Aragaw WW; Cole MS; Jachak G; Ragunathan P; Sharma S; Harikishore A; Grüber G; Dick T; Aldrich CC
Bioorg Med Chem; 2022 Nov; 74():117046. PubMed ID: 36228522
[TBL] [Abstract][Full Text] [Related]
25. Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
Njire M; Wang N; Wang B; Tan Y; Cai X; Liu Y; Mugweru J; Guo J; Hameed HMA; Tan S; Liu J; Yew WW; Nuermberger E; Lamichhane G; Liu J; Zhang T
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438933
[TBL] [Abstract][Full Text] [Related]
26. Global status of phenotypic pyrazinamide resistance in
Wang Z; Tang Z; Heidari H; Molaeipour L; Ghanavati R; Kazemian H; Koohsar F; Kouhsari E
J Chemother; 2023 Nov; 35(7):583-595. PubMed ID: 37211822
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009.
Kurbatova EV; Cavanaugh JS; Dalton T; Click ES; Cegielski JP
Clin Infect Dis; 2013 Oct; 57(8):1081-93. PubMed ID: 23840002
[TBL] [Abstract][Full Text] [Related]
28. Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance.
Mustazzolu A; Iacobino A; Giannoni F; Piersimoni C; ; Fattorini L
J Clin Microbiol; 2017 Dec; 55(12):3552-3553. PubMed ID: 28904184
[No Abstract] [Full Text] [Related]
29. Identification of Novel Mutations in LprG (
Shi W; Chen J; Zhang S; Zhang W; Zhang Y
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686155
[TBL] [Abstract][Full Text] [Related]
30. How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide.
Köser CU; Cirillo DM; Miotto P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571824
[TBL] [Abstract][Full Text] [Related]
31. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide.
Petrella S; Gelus-Ziental N; Maudry A; Laurans C; Boudjelloul R; Sougakoff W
PLoS One; 2011 Jan; 6(1):e15785. PubMed ID: 21283666
[TBL] [Abstract][Full Text] [Related]
32. Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.
Singh P; Wesley C; Jadaun GP; Malonia SK; Das R; Upadhyay P; Faujdar J; Sharma P; Gupta P; Mishra AK; Singh K; Chauhan DS; Sharma VD; Gupta UD; Venkatesan K; Katoch VM
J Clin Microbiol; 2007 Jan; 45(1):76-80. PubMed ID: 17093022
[TBL] [Abstract][Full Text] [Related]
33. A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis.
Ramirez-Busby SM; Rodwell TC; Fink L; Catanzaro D; Jackson RL; Pettigrove M; Catanzaro A; Valafar F
Sci Rep; 2017 Jun; 7(1):3790. PubMed ID: 28630430
[TBL] [Abstract][Full Text] [Related]
34. A robust computational quest: Discovering potential hits to improve the treatment of pyrazinamide-resistant Mycobacterium tuberculosis.
Shahab M; de Farias Morais GC; Akash S; Fulco UL; Oliveira JIN; Zheng G; Akter S
J Cell Mol Med; 2024 Apr; 28(8):e18279. PubMed ID: 38634203
[TBL] [Abstract][Full Text] [Related]
35. Prediction of Mycobacterium tuberculosis pyrazinamidase function based on structural stability, physicochemical and geometrical descriptors.
Supo-Escalante RR; Médico A; Gushiken E; Olivos-Ramírez GE; Quispe Y; Torres F; Zamudio M; Antiparra R; Amzel LM; Gilman RH; Sheen P; Zimic M
PLoS One; 2020; 15(7):e0235643. PubMed ID: 32735615
[TBL] [Abstract][Full Text] [Related]
36. Insight into novel clinical mutants of RpsA-S324F, E325K, and G341R of
Khan MT; Rehaman AU; Junaid M; Malik SI; Wei DQ
Comput Struct Biotechnol J; 2018; 16():379-387. PubMed ID: 30402208
[TBL] [Abstract][Full Text] [Related]
37. Biphasic Medium Using Nicotinamide for Detection of Pyrazinamide Resistance in
Thuansuwan W; Chuchottaworn C; Nakajima C; Suzuki Y; Chaichanawongsaroj N
Antibiotics (Basel); 2024 Jun; 13(6):. PubMed ID: 38927229
[TBL] [Abstract][Full Text] [Related]
38. Insights Into Mutations Induced Conformational Changes and Rearrangement of Fe
Nangraj AS; Khan A; Umbreen S; Sahar S; Arshad M; Younas S; Ahmad S; Ali S; Ali SS; Ali L; Wei DQ
Front Mol Biosci; 2021; 8():633365. PubMed ID: 34095218
[TBL] [Abstract][Full Text] [Related]
39. Mechanistic analysis of A46V, H57Y, and D129N in pyrazinamidase associated with pyrazinamide resistance.
Khan MT; Chinnasamy S; Cui Z; Irfan M; Wei DQ
Saudi J Biol Sci; 2020 Nov; 27(11):3150-3156. PubMed ID: 33100877
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.
Gopal P; Grüber G; Dartois V; Dick T
Trends Pharmacol Sci; 2019 Dec; 40(12):930-940. PubMed ID: 31704175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
